医学
结直肠癌
肿瘤科
内科学
微小残留病
佐剂
临床试验
辅助化疗
疾病
临床终点
循环肿瘤DNA
随机对照试验
代理终结点
癌症
乳腺癌
白血病
作者
Seiya Sato,Yoshiaki Nakamura,Eiji Oki,Takayuki Yoshino
标识
DOI:10.1016/j.clcc.2022.12.001
摘要
The body of evidence supporting the utility of the detection of molecular residual disease (MRD) in resected colorectal cancer (CRC) using circulating tumor DNA (ctDNA) analysis is rapidly growing. Furthermore, this evidence provides the rationale for escalation and de-escalation adjuvant chemotherapy (ACT) strategies using ctDNA MRD analysis. This has led to various randomized clinical trials, and CIRCULATE-Japan is one of the largest of these trial platforms. In this review, we provide an overview of the potential utility of ctDNA-based MRD detection for escalation and de-escalation ACT approaches. Furthermore, we highlight the feasibility using ctDNA clearance as a surrogate endpoint for ACT trials in patients with resected CRC, based on findings of the CIRCULATE-Japan project.
科研通智能强力驱动
Strongly Powered by AbleSci AI